OncView™ Podcast: Advances in Systemic Therapy of Differentiated Thyroid Cancer

Podcast

In an OncView™ program, Lori Wirth, MD, shared her insights into the current treatment of patients with differentiated thyroid cancer.

As part of its OncView™ program, CancerNetwork hosted a discussion Lori Wirth, MD, associate professor of medicine at Harvard Medical School and medical director of the Center for Head and Neck Cancers at Massachusetts General Hospital in Boston, who shared her perspective on updates in the treatment of second-line radioiodine-refractory differentiated thyroid cancer, or DTC.

In the video series, some of the content discussed included:

To watch more videos in the CancerNetwork® OncView™ series, visit cancernetwork.com/oncview.

Don’t forget to subscribe to the “Oncology Peer Review On-The-Go” podcast on Apple Podcasts, Spotify, or anywhere podcasts are available.

Recent Videos
Findings may help providers and patients with head and neck cancer consider whether to proceed with radiotherapy modalities, such as proton therapy or IMRT.
Study results appear to affirm anecdotal information from patients with head and neck cancer related to taste changes during and after radiotherapy.
Noah S. Kalman, MD, MBA, describes the rationale for using a test to measure granular details of taste change in patients undergoing radiotherapy for HNC.
The use of a single-port robot may allow for surgically treating more patients with head and neck cancer in a more timely manner, according to Hilary McCrary, MD, MPH.
Treatment with toripalimab does not yield the same vascular toxicity seen with pembrolizumab in patients with advanced or metastatic nasopharyngeal carcinoma, according to Barbara Burtness, MD.
Overall survival also appears to improve with toripalimab compared with chemotherapy among patients with metastatic or advanced nasopharyngeal carcinoma.
Related Content
Durvalumab Does Not Improve Outcomes Vs Cetuximab in Head and Neck Cancer

Durvalumab Does Not Improve Outcomes Vs Cetuximab in Head and Neck Cancer

Tim Cortese
December 1st 2024
Article

For patients with head and neck squamous cell carcinoma and contraindications to cisplatin, durvalumab yielded worse PFS vs cetuximab.

Andrew M. Evens, DO, MBA, MSc, discusses the importance of meeting the emotional and physical needs of cancer survivors to help them lead fruitful lives.

Ensuring Holistic, Individualized Transitions of Care for Cancer Survivors

Andrew M. Evens, DO, MBA, MSc
December 9th 2024
Podcast

Andrew M. Evens, DO, MBA, MSc, discusses the importance of meeting the emotional and physical needs of cancer survivors to help them lead fruitful lives.

While cisplatin was in shortage, clinicians were forced to prescribe costlier alternatives for patients with head and neck cancer.

Cisplatin Shortage Shifted Chemo Utilization to Costlier Therapies for HNC

Roman Fabbricatore
October 16th 2024
Article

While cisplatin was in shortage, clinicians were forced to prescribe costlier alternatives for patients with head and neck cancer.

Tanios S. Bekaii-Saab, MD, provides an overview of current therapy options and ongoing initiatives involving targetable alterations in those with pancreatic cancer.

Advancing Research and Targeting Genomic Alterations in Pancreatic Cancer

Tanios S. Bekaii-Saab, MD, FACP
November 25th 2024
Podcast

Tanios S. Bekaii-Saab, MD, provides an overview of current therapy options and ongoing initiatives involving targetable alterations in those with pancreatic cancer.

The FDA granted traditional approval to selpercatinib for patients with advanced or metastatic medullary thyroid cancer with a RET mutation.

FDA Approves Selpercatinib for RET Fusion+ Medullary Thyroid Cancer

Gina Mauro
September 27th 2024
Article

The FDA granted traditional approval to selpercatinib for patients with advanced or metastatic medullary thyroid cancer with a RET mutation.

“We are now able to increase the lifespan in some of these most deadly forms of thyroid cancer solely due to gene profiling and targeted medicine,” said Geoffrey David Young, MD, PhD, FACS

Taking a Multidisciplinary Approach to Thyroid Cancer Treatment

Harrison Widelitz
September 27th 2024
Article

“We are now able to increase the lifespan in some of these most deadly forms of thyroid cancer solely due to gene profiling and targeted medicine,” said Geoffrey David Young, MD, PhD, FACS.